Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Epsilogen, a UK-based spinout of King’s College London working on cancer treatments that exploit immunoglobulin E antibodies, pocketed £30.75m ($41.2m) in a series B round backed by commercialisation firm Epidarex Capital yesterday. The round was led by Novartis Venture Fund on behalf of pharmaceutical firm Novartis, and also included Alsa Ventures, 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property. Epsilogen, then known as Item Therapeutics, previously closed a $6.4m series A round in 2018 backed…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).